Leave Your Message

Nnukwu ọrịa leukemia Lymphoblastic (T-ALL) -04

Onye ọrịa: XXX

okike: Nwoke

Afọ: 15 afọ

Obodo:Sweden

Nchọpụta nchọpụtaNnukwu ọrịa leukemia Lymphoblastic (T-ALL)

    Nnukwu ọrịa leukemia lymphoblastic cellular nwere nlọghachi azụ n'oge transplant yana usoro leukemia nke sistemu ụjọ jikọtara ya.


    Onye ọrịa ahụ bụ nwoke dị afọ 15, a chọpụtara na ọ nwere nnukwu ọrịa leukemia T-cell (T-ALL nwere STIL-TAL1 positivity, mkpụrụ ndụ prognostic na-adịghị mma) na njedebe nke Disemba 2020, wee gwọọ ya n'ụlọ ọgwụ mpaghara nwere ọtụtụ. cycles nke chemotherapy mgbe niile iji nweta mgbaghara zuru oke. A na-eme transplantation nke nna na nwa hemizygous hematopoietic stem cell na 2 June 2021, mana ọ dị nwute na ahụrụ nlọghachite ụmị ọkpụkpụ n'ime ọnwa 3 ka a tụgharịrị ya, na usoro 1 chemotherapy adịghị arụ ọrụ. Otu usoro ọgwụgwọ chemotherapy adịghị arụ ọrụ, n'otu oge ahụ, ọ malitere ntì na-agbapụta agbagọ na ntapu nke ikuku, nkuku gbagọrọ agbagọ nke ọnụ, na nkwụsịtụ lumbar na-atụ aro ịmalite ọrịa leukemia nke usoro nhụjuanya etiti.


    T-ALL nwere STIL-TAL1 positivity, nlọghachi azụ n'oge mgbe transplantation allogeneic, jikọtara ya na leukemia sistem ụjọ nke etiti, bụ ikpe siri ike ịgwọ n'oge na-enweghị CAR-T. Nna nwata ahụ jụrụ banyere Director Zhang Qian nke Ụlọ Ọgwụ Ludoupe site na ndị enyi ya, na mgbe ha nwesịrị nkwurịta okwu zuru ezu, ha bịara na Yanda Ludoupe Hospital, na-achọ ịlụ ọgụ maka ndụ ha site na ịdebanye aha na CAR-T ụlọ ọgwụ.


    CAR-T nke mbụ dara, mkpụrụ ndụ etuto mụbara ngwa ngwa, ndụ ya nọkwa n'ihe egwu.

    Na 26 Ọktoba 2021, a nabatara onye ọrịa na ngalaba mbụ nke Ngalaba Hematology. N'ihi mmụba ngwa ngwa nke mkpụrụ ndụ etuto ahụ, enwere ike ịgwọ onye ọrịa naanị site na chemotherapy iji belata ibu etuto ahụ, yana ntụtụ ngwungwu lumbar nke ọgwụ chemotherapeutic. Mmiri cerebrospinal adịghị mma. Mgbe ọnọdụ onye ọrịa ahụ kwụsiri ike, a na-achịkọta lymphocytes nna ya maka omenala CAR-T cell, na 19 November, a na-etinye mkpụrụ ndụ CD7 CAR-T na-enye onyinye n'ime onye ọrịa ahụ.


    Ụbọchị ole na ole ka mmịnye ahụ gasịrị, tupu mgbasawanye nke mkpụrụ ndụ CAR-T, mkpụrụ ndụ tumor onye ọrịa mụbara ngwa ngwa ọzọ, a pụkwara ịhụ ọnụ ọgụgụ dị ukwuu nke progenitor n'ime ọbara dị n'akụkụ, ya mere CAR-T mbụ dara.


    Ọ mere na ụlọ ọgwụ anyị na-eme nnwale ụlọ ọgwụ nke eluigwe na ala CAR-T (CD7 UCAR-T) maka nnukwu ọrịa leukemia T-lymphoblastic n'oge a. Ndị nne na nna nwere oke nchegbu ma kwuo na ha chọrọ ịnwale nwa ha ọbụlagodi ma ọ bụrụ na enwere ohere 1%. Onye isi Zhang Qin so ezinaụlọ ahụ kparịtara ụka ọzọ wee kpebie ịdebanye aha nwa ha n'ule ụlọ ọgwụ CD7 UCAR-T anyị.


    # Mgbaghara zuru oke mgbe ị debanyere aha na CD7 UCAR-T nnwale ụlọ ọgwụ, ugbu a ọnwa 2 ka ọ gafechara transplant

    Na 2 Disemba, a na-etinye onye ọrịa ahụ na sel CD7 U-CART, bụ ndị a na-eji belata ibu ụbụrụ ahụ mgbe ọ na-enye ọgwụgwọ nkwado symptomatic na-arụ ọrụ. Na 2 Disemba, etinyere sel CD7 U-CART n'ime onye ọrịa. Mgbe infusion ahụ gasịrị, onye ọrịa ahụ nwere ahụ ọkụ na-adịgide adịgide ruo ọtụtụ ụbọchị ma nwee mmụọ dara ogbenye. Ihe ịrịba ama dị mkpa nke onye ọrịa ahụ ji nwayọọ nwayọọ kwụsie ike, ọ̀tụ̀tụ̀ shuga dị n'ahụ ahụ ji nwayọọ nwayọọ mee ka ọ dị mma mgbe ndị ọrụ ahụ ike gwọchara onye ọrịa ọgwụ mgbochi ọrịa na ume ume ọhụrụ.


    Ọkpụkpụ na ọkpụkpụ ọkpụkpụ na 18th na 28th ụbọchị mgbe CD7 UCAR-T infusion gosipụtara mgbaghara zuru oke na MRD na-adịghị mma. Ọnọdụ uche nwata ahụ na-akawanye mma, agụụ ya weghachiri ya, ọ malitekwara ịmaliteghachi, nne ya, bụ onye na-akwa akwa kwa ụbọchị, mechara hụ ịmụmụ ọnụ ọchị nke a na-ahụbeghị kemgbe ogologo oge.


    Ugbu a, onye ọrịa ahụ enwetala HSCT nke abụọ na-arụkọ ọrụ ọnụ n'ụlọ ọgwụ anyị maka ọnwa 2, ọrịa ahụ ka na-agbaghara kpamkpam.

    nkọwa2

    Fill out my online form.